Video

Dr. Tolaney on the Evolution of Adjuvant Treatment for HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the evolution of adjuvant treatment for patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the evolution of adjuvant treatment for patients with HER2-positive breast cancer.

There have been outcomes from 6 pivotal studies demonstrating that adding trastuzumab (Herceptin) to chemotherapy dramatically improves disease-free and overall survival. Despite this, 15% of patients with HER2-positive disease still recur, says Tolaney.

Results from the CLEOPATRA study suggested that adding pertuzumab (Perjeta) to trastuzumab dramatically improved survival by 16 months. The NeoSphere, TRYPHAENA, and APHINITY studies were also positive for the combination, and led to the FDA approval of the regimen.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Ami Umesh Badami, MD
Premal Thaker, MD, MS